• Briacell Therapeutics announced four preclinical immunotherapy posters accepted for the SITC annual meeting in Phoenix on Nov. 4-8, 2026.
• Results will be presented in the future, not previously released, with posters scheduled for Nov. 6-7.
• Work highlights early evidence that its vaccine platform could drive broad, persistent anti-tumor immune responses across multiple cancers.
• Separate posters outline tumor-targeted checkpoint approaches, including a soluble CD80 program, aimed at reactivating immune cells in tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060730PRIMZONEFULLFEED9840089) on October 06, 2026, and is solely responsible for the information contained therein.